Jeffrey A. Bluestone
Affiliations: | University of Chicago, Chicago, IL |
Area:
Cell Biology, Immunology, Molecular BiologyGoogle:
"Jeffrey Bluestone"Children
Sign in to add trainee| Maria-Luisa Alegre | grad student | Chicago | |
| Ingrid C. Rulifson | grad student | 2000 | Chicago |
| Keshava Rajagopal | grad student | 2001 | Chicago |
| Cristina Penaranda | grad student | 2005-2010 | UCSF (Microtree) |
| Anne I Sperling | post-doc | (Neurotree) | |
| Leonardo M.R. Ferreira | post-doc | 2016- | UCSF |
| Daniel Bryan Goodman | post-doc | 2017- | UCSF (Chemistry Tree) |
| Brian T. Fife | post-doc | 2002-2007 | UCSF (Microtree) |
| Todd M. Brusko | post-doc | 2008-2011 | (Epi Tree) |
| Gaurav Chopra | post-doc | 2013-2016 | UCSF (Computational Biology Tree) |
Collaborators
Sign in to add collaborator| Eugene P Brandon | collaborator | (Neurotree) | |
| Yapeng Su | collaborator | (Chemistry Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Bluestone JA, McKenzie BS, Beilke J, et al. (2023) Opportunities for Treg cell therapy for the treatment of human disease. Frontiers in Immunology. 14: 1166135 |
| Goodman DB, Azimi CS, Kearns K, et al. (2022) Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies. Science Translational Medicine. 14: eabm1463 |
| VanDyke D, Iglesias M, Tomala J, et al. (2022) Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell Reports. 41: 111478 |
| Su Y, Yuan D, Chen DG, et al. (2022) Multiple early factors anticipate post-acute COVID-19 sequelae. Cell |
| Balcerek J, Shy BR, Putnam AL, et al. (2021) Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience. Frontiers in Immunology. 12: 744763 |
| Muller YD, Ferreira LMR, Ronin E, et al. (2021) Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance. Frontiers in Immunology. 12: 686439 |
| Dong S, Hiam-Galvez KJ, Mowery CT, et al. (2021) The effects of low-dose IL-2 on Treg adoptive cell therapy in patients with Type 1 diabetes. Jci Insight |
| Muller YD, Nguyen DP, Ferreira LMR, et al. (2021) The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. Frontiers in Immunology. 12: 639818 |
| Su Y, Chen D, Yuan D, et al. (2020) Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell |
| Lee JC, Mehdizadeh S, Smith J, et al. (2020) Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Science Immunology. 5 |